Mobile Edge Cloud: Intelligent deployment and services for 5G Indoor Network

This thesis was submitted for the award of doctor of Philosophy and was awarded by Brunel University LondonFifth-Generation (5G) mobile networks are expected to perform according to the stringent performance targets assigned by standardization committees. Therefore, significant changes are proposed to the network infrastructure to achieve the expected performance levels. Network Function Virtualization, cloud computing and Software Defined Networks are some of the main technologies being utilised to ensure flexible network design, with optimum performance and efficient resource utilization. The aforementioned technologies are shifting the network architecture into service-based rather device-based architecture. In this regard, this thesis provides experimental investigation, design, implementation and evaluation of various multimedia services along with integration design and caching solution for 5G indoor network. The multimedia services are targeting the enhancement of UEs’ Quality of Experience, by exploiting the intelligence offered by the synergy between SDN and NFV technologies, to design and develop new multimedia solutions with improved QoE. The caching solution is designed to achieve a good trade-off between latency reduction and resource utilization that satisfies efficient network performance and resource utilization. The proposed network integration design targets deploying IoRL gNB with its innovative intelligent services. It have successfully achieved lower overhead signalling compared to the traditional network architectures. Whilst all of the proposed solutions have proven to provide enhancement to the system performance, the testing results for the multimedia services showed high QoS performance parameters in the form of zero packet loss due to route switching, very high throughput and 0.03 ms jitter. The caching solution test results provided up to 300% server utilization improvement (based on the deployed scenario) with negligible extra delay cost (0.5ms). As for the proposed integration design, the quantification of the performance enhancement is represented by the amount of the reduced overhead signalling. In the case of Intra-secondary gNB handover within the same Main eNB, the back-haul signalling for the AMF was reduced 100% while the overall overhead signalling is reduced by 50% compared to traditional deployment architecture.European Union’s Horizon 2020 research progra

Smart Television Services Using NFV/SDN Network Management

International audienceIntegrating joint network function virtualization (NFV) and software-defined networks (SDNs) with digital televisions (TVs) into home environments, has the potential to provide smart TV services to users, and improve their quality of experience (QoE). In this regard, this paper focuses on one of the next generation services so-called follow me service (FMS). FMS is a service offered by 5gNB to user equipments (UEs) in indoor environments (e.g., home), it enables its clients to use their smart phones to select media content from content servers, then cast it on the nearest TV set (e.g., living room) and continue watching on the next TV set (e.g., kitchen) while moving around the indoor coverage area. FMS can be provisioned by utilizing UEs geoloca-tion information and robust mechanisms for switching between multiple 5G radio access technologies (RATs), based on the intelligence of the SDN/NFV intelligent home IP gateway of the Internet of Radio Light (IoRL) project paradigm. In view that the actual IoRL system is at its early development stage, we step forward by using Mininet platform to integrate SDN/NFV virtualization into 5G multi-RAT scenario and provide performance monitoring with measurements for the identified service. Simulation results show the effectiveness of our proposal under various use case scenarios by means of minimizing the packet loss rate and improving QoE of the home users. Index Terms-Software defined networks, network function virtualisation, quality of experience, Internet of radio light, intelligent home IP gateway

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

5G Internet of radio light services for supermarkets

International audienc

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Background: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18-49, 50-69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population